SRR35579799
— · D
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- D
- subtype
- D
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- INTERFERON_ALPHA_RESPONSE+0.590
- ALLOGRAFT_REJECTION+0.580
- INTERFERON_GAMMA_RESPONSE+0.560
- REACTIVE_OXYGEN_SPECIES_PATHWAY+0.530
- INFLAMMATORY_RESPONSE+0.440
- COMPLEMENT+0.430
- COAGULATION+0.400
- IL6_JAK_STAT3_SIGNALING+0.390
- IL2_STAT5_SIGNALING+0.300
- CHOLESTEROL_HOMEOSTASIS+0.280
Top 10 suppressed
- PROTEIN_SECRETION-0.320
- E2F_TARGETS-0.240
- MYC_TARGETS_V2-0.220
- DNA_REPAIR-0.170
- ESTROGEN_RESPONSE_EARLY-0.170
- HEDGEHOG_SIGNALING-0.170
- TGF_BETA_SIGNALING-0.170
- G2M_CHECKPOINT-0.160
- ESTROGEN_RESPONSE_LATE-0.150
- SPERMATOGENESIS-0.130
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
6 twins match this tumor's tissue · 4 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | BS_6NTXGQAC | Ganglioglioma | — | 0.853 |
| 2 | TCGA-A8-A0A7-01A-11R-A00Z-07 | — | D | 0.853 |
| 3 | SRR25617878 | — | D | 0.843 |
| 4 | TCGA-A2-A0T1-01A-21R-A084-07 | — | D | 0.828 |
| 5 | TCGA-AR-A1AO-01A-11R-A12P-07 | — | A | 0.825 |
| 6 | SRR1079591 | GTEX | — | 0.823 |
| 7 | TCGA-FD-A5BS-01A-21R-A26T-07 | — | — | 0.823 |
| 8 | R13 | — | — | 0.822 |
| 9 | MDT-AP-0410 | Med | Medulloblastoma | 0.820 |
| 10 | BS_CS66RYDA | Schwannoma | — | 0.819 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 33 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| INTERFERON_ALPHA_RESPONSE | 0.590 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.580 | Idelalisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.560 | Idelalisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.530 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.440 | Idelalisib | — uncovered |
| COMPLEMENT | 0.430 | Inavolisib | — uncovered |
| COAGULATION | 0.400 | Binimetinib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.390 | Inavolisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.300 | Idelalisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.280 | Remibrutinib | — uncovered |
| APOPTOSIS | 0.250 | Idelalisib | — uncovered |
| KRAS_SIGNALING_UP | 0.240 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.230 | Remibrutinib | — uncovered |
| APICAL_JUNCTION | 0.220 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.200 | Cobimetinib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.200 | Inavolisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.180 | Inavolisib | — uncovered |
| KRAS_SIGNALING_DN | 0.180 | Remibrutinib | — uncovered |
| P53_PATHWAY | 0.180 | Idelalisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.160 | Inavolisib | — uncovered |